Logo

Caliper’s NovaScreen Division Signs Screening Deal with Wyeth

Jun 26, 2006

NEW YORK, June 26 (GenomeWeb News) - NovaScreen Biosciences, a Caliper Life Sciences company, will perform high-throughput screening for Wyeth Pharmaceuticals, NovaScreen said today.

 

Under the terms of the agreement, NovaScreen will use Caliper's LabChip 3000 microfluidic screening platform to screen 500,000 compounds against an inflammatory target.

 

According to NovaScreen, the LabChip 3000 technology helps eliminate false positives in the primary screen.

 

Financial details of the agreement were not disclosed.

 

Caliper purchased NovaScreen for approximately $30 million last October.

Breaking News
The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.